Linked Life Data

2138004

Source:http://linkedlifedata.com/resource/pubmed/id/2138004

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3 Pt 1
pubmed:dateCreated
1990-4-12
pubmed:abstractText
Eighteen patients with progressive/locally recurrent cancer of the stomach were given therapy with MMC, ADM, CDDP, Etoposide (VP-16), and 5'DFUR (MAC-VD therapy). Drugs were administered intravenously with MMC 10 mg/m2, ADM 20 mg/m2, and CDDP 50 mg/m2 on day 1; orally with etoposide 100 mg/day for five consecutive days from day 3; and orally with 5'DFUR 600 mg/day for three weeks from day 3 followed by discontinuation for one subsequent week. This drug regimen was one course of the treatment and repeated as far as possible. There were 16 evaluable cases; the sex distribution was ten males and six females. Patients ranged in age from 43 to 78 years. P.S. 1 was two cases; 2 ten cases; and 3 four cases. The overall response rate, CR + PR, was 1 + 7/16 (50%), while this rate for primary disease was 2 + 5/16 (43.8%). Of the two CR cases, one primary lesion became operable and CR was demonstrated histologically. The overall response rates, CR + PR, for metastatic lesions were 1 + 3/9 (44.4%) for the liver; 0 + 1/4 (25.0%) for the abdominal lymph nodes; 0 + 1/2 (50.0%) for the superficial lymph nodes; 0 + 1/2 (50.0%) for the bones; and 0 + 1/1 (100%) for the lung. The median duration of the response was 3.7 months (range between 1.5 and 8.2+) and the median duration of survival 5.1+ months (range between 2.2+ and 13.3+). At the same time, the hematological side effects of both leukocytopenia and hypohemoglobinemia were seen in 43.8% of the cases. Non-hematological side effects included alopecia in 18.8% and nausea/vomiting in 12.5%. There was no case of discontinuation due to side effects. It was concluded that the therapy with MMC, ADM, CDDP, etoposide and 5'DFUR (MAC-VD therapy) proved to be a very promising drug regimen in the treatment of stomach cancer with high rates of response and is expected to be a step forward in the establishment of interdisciplinary treatment.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
397-401
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:2138004-Administration, Oral, pubmed-meshheading:2138004-Adult, pubmed-meshheading:2138004-Aged, pubmed-meshheading:2138004-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:2138004-Cisplatin, pubmed-meshheading:2138004-Doxorubicin, pubmed-meshheading:2138004-Drug Administration Schedule, pubmed-meshheading:2138004-Drug Evaluation, pubmed-meshheading:2138004-Etoposide, pubmed-meshheading:2138004-Female, pubmed-meshheading:2138004-Floxuridine, pubmed-meshheading:2138004-Humans, pubmed-meshheading:2138004-Infusions, Intravenous, pubmed-meshheading:2138004-Lymphatic Metastasis, pubmed-meshheading:2138004-Male, pubmed-meshheading:2138004-Middle Aged, pubmed-meshheading:2138004-Mitomycin, pubmed-meshheading:2138004-Mitomycins, pubmed-meshheading:2138004-Neoplasm Recurrence, Local, pubmed-meshheading:2138004-Stomach Neoplasms
pubmed:year
1990
pubmed:articleTitle
[A study of combined chemotherapy with MMC, ADM, CDDP, etoposide (VP-16), 5'DFUR (MAC-VD therapy) in advanced cancer and local relapse of the stomach].
pubmed:affiliation
Dept. of Gastroenterology, Medical Center for Adults.
pubmed:publicationType
Journal Article, English Abstract